MedPath

CGM - Reimagine Primary Care

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Device: Dexcom G6
Device: Contour NextOne
Registration Number
NCT04413578
Lead Sponsor
Intermountain Health Care, Inc.
Brief Summary

To assess the impact of continuous glucose monitoring versus standard of care (e.g. a finger-prick protocol using a glucometer) on clinical outcomes, healthcare utilization, and cost in patients with type I or II diabetes treated within the Reimagine Primary Care clinics.

Detailed Description

This is a parallel randomized controlled trial. Eligible patients who consent will be randomized to one of two groups: (1) the intervention group who will be given a Dexcom G6 for CGM, or (2) the control group who will follow their current standard finger-prick protocol via a provided Contour Next ONE glucometer. The CGM group must download the Dexcom G6 and Clarity mobile apps for data capture, whereas the standard of care group will use the Contour Next mobile app for their respective readings.

The Dexcom G6 captures real-time, dynamic glucose data every five minutes. Devices used in this study are FDA approved and commercially available.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
101
Inclusion Criteria
  • Type 1 or type 2 diabetes mellitus with a HbA1c ≥6.5%
  • Patients that are currently managing their glucose levels for diabetes with a glucose meter (or will be prescribed one by their healthcare provider)
  • Patients that are treated within the four Reimagine Primary Care clinics (Cottonwood Family Medicine, Cottonwood Senior, Avenues Internal Medicine, and Holladay Internal Medicine). • Patients 18-80 years of age
Exclusion Criteria
  • Patients that are not managing their glucose levels for diabetes (and not advised to use a glucose monitor by their physician)
  • Patients that are not treated within the four Reimagine Primary Care clinics
  • Patients less than 18 years of age, and 81 years of age and older
  • Patients with a diagnosis of dementia
  • If the patient is currently using a Continuous Glucose Monitor
  • Patients with previous hospitalization for hypoglycemia within the last 18 months
  • No access to a mobile phone to download the Dexcom or Contour Next applications
  • Patients who are pregnant or planning to become pregnant over the course of their six-month participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dexcom G6 (Intervention Group)Dexcom G6• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
Contour NextOne (Standard of Care) GlucometerContour NextOne• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
Primary Outcome Measures
NameTimeMethod
HbA1c Variation6 months

Coefficient of variation in HbA1c levels before, during and end of study completion.

HbA1c Range6 months

Variation of range in HbA1c levels before, during and end of study completion.

Secondary Outcome Measures
NameTimeMethod
Current Diabetes Standards6 months

Current HEDIS performance on diabetes and behavioral health measures.

Behavioral Changes6 months

Subjects will complete a self reported survey related to behavioral changes at end of study to assess self empowered behavioral changes after using the devices (e.g. feeling more empowered to self-manage care, engaged with changing healthcare behaviors, and patient perceptions of the technology).

Hypoglycemic Events6 months

Frequency of hypoglycemic events during the study.

Healthcare Utilization6 months

Healthcare utilization per count of inpatient/outpatient visits.

Glycemic Variability6 months

Glycemic variability per mean amplitude of glycemic excursion (MAGE)

Emergency Room Visits6 months

Emergency department visits per 1000 rate, overall and for patients with diabetes, and hospitalization per 1000 rate related to.

Healthcare Cost6 months

Cost per patient of healthcare for Emergency Room visits, blood draws, inpatient/outpatient services, medications etc.

Trial Locations

Locations (4)

Holladay Internal Medicine

🇺🇸

Holladay, Utah, United States

Intermountain Senior Clinic

🇺🇸

Murray, Utah, United States

Intermountain Cottonwood Family Practice

🇺🇸

Murray, Utah, United States

Avenues Internal Medicine

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath